Allergan to merge with Pfizer after a 90% sales increase

Allergan reported what it described as “continued exceptional performance” with sales up by 90 percent to $4.1 billion for the quarter ended Sept. 30 as compared to the previous year's third quarter. The performance was driven by growth in the company's U.S. Brands, medical aesthetics, international brands and Anda distribution ...

Keep reading this article by becoming a member


Enjoy unrestricted access to Eyewear Intelligence

To continue reading this article subscribe now

  • Unlimited access to our highly trusted industry insights and analysis
  • Benchmark yourself against the market and competitors
  • Find inspiration to drive your business forward
  • Stay up to date with new business models and startups

If you aren’t ready to subscribe now, you can REGISTER FOR FREE. Already an Eyewear Intelligence subscriber? Sign in here.